Categories Uncategorized

Psychedelics May Alter How People View the Universe

Research on psychedelic substances has led to the discovery of the numerous benefits that these substances possess, which could be utilized in the treatment of various mental health conditions. A recent study has found that psychedelic substances can alter an individual’s beliefs on metaphysics. Metaphysics refers to a branch of philosophy that focuses on “being.”

Some believe that every individual has metaphysical beliefs, whether they are conscious of those beliefs or not. Sharpening an individual’s understanding of metaphysics can be achieved with different techniques, including meditation. Having a near-death experience may also sharpen one’s understanding of the same.

In an effort to confirm this, researchers led by Dr. Christopher Timmermann measured the metaphysical stance of a group of people before and after they consumed psychedelics in a psychedelic ceremony. Timmermann is a PhD candidate at the Centre for Psychedelic Research at Imperial College London.

For their study, the researchers recruited 900 participants who filled out a survey on the realms of existence. The aim of these questions was to determine the participants’ baseline metaphysical beliefs. After this, each participant consumed psilocybin at the psychedelic ceremony. Once the ceremony was complete, each participant answered the questions again —  twice — four weeks and six months after they answered the first survey.

The researchers found that the participants shifted their views towards idealism, nonnaturalism or transcendentalism after the ceremony, from beliefs that included physicalism or materialism, noting that the impact of the psychedelic was most profound for individuals who ingested the drug for the first time. The researchers also noted that the individuals’ stances of any kind shifted to more moderate or mixed views, adding that the participants also reported improvements in mental health.

Thereafter, the researchers also conducted a clinical trial that involved only 60 participants. Of this number, half were given psilocybin while the remaining number received an antidepressant known as escitalopram. The researchers found that the results were almost the same, with participants that received psilocybin shifting toward more supernatural and idealistic conceptions of the universe.

Timmermann noted that the study offered evidence that psychedelic substances shifted beliefs on the nature of reality, explaining that these beliefs were at the core of how human beings organized society. In the study, which will soon be published in the “Scientific Reports” journal, the researchers recommended that individuals participating in future studies which involve the use of psychedelics be advised that their views of the world may be modified by their participation.

With the high rate at which research on psychedelic compounds is being done, it may not be long before several medicinal formulations from companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are approved by regulators and become available to the patients who need them.

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are available in the company’s newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 months ago